SLC9A1 Knockout SK-MEL-28 Cell Line

The SLC9A1 Knockout SK-MEL-28 Cell Line is a CRISPR/Cas9-edited human melanoma cell line featuring targeted disruption of the SLC9A1 gene. This cell line serves as a loss-of-function model to investigate the biological roles of the Na+/H+ exchanger 1 (NHE1) in melanoma biology. By ablating SLC9A1 expression, researchers can dissect pH-regulatory mechanisms and their impact on tumor cell behavior without confounding background activity. The knockout cell line is generated from the parental SK-MEL-28 line through CRISPR/Cas9-mediated gene disruption, ensuring stable elimination of NHE1 protein production. It is provided as a ready-to-use in vitro model for advanced cancer research applications.

SK-MEL-28 is a widely used human melanoma cell line derived from a primary cutaneous melanoma, characterized by epithelial morphology and a homozygous BRAF V600E mutation. This oncogenic driver constitutively activates the MAPK/ERK pathway, mimicking a common genetic lesion in malignant melanoma. The cell line is established as a robust model for studying tumorigenesis, metastatic progression, and therapeutic resistance. SK-MEL-28 cells exhibit aggressive migratory and invasive properties, making them particularly suitable for evaluating the contribution of microenvironmental cues such as pH dynamics to melanoma aggressiveness.

SLC9A1 encodes the ubiquitously expressed NHE1 protein, an integral membrane transporter that exchanges one intracellular H+ for one extracellular Na+, thereby alkalinizing the cytoplasm and regulating cell volume. NHE1 activity is governed by numerous upstream regulators, including growth factors like EGF and PDGF, integrin-mediated adhesion, G protein-coupled receptor ligands, cytosolic acidification, calmodulin binding, and Ca2+ signals. Activated NHE1 interacts with calmodulin, the calcineurin B homologous protein CHP1, and ERM family proteins (ezrin, radixin, moesin), which link it to the actin cytoskeleton. Downstream, NHE1-mediated pHi increase promotes cytoskeletal reorganization, focal adhesion turnover through ERK1/2 and myosin light chain phosphorylation, and matrix metalloproteinase activation, facilitating cell migration and invasion. Functionally, NHE1 integrates signals from the MAPK/ERK, PI3K/AKT, and RhoA/ROCK pathways??converging on effectors such as MEK, ERK, AKT, RhoA, ROCK, LIMK, and cofilin??to coordinate protrusion dynamics and matrix degradation.

In the SK-MEL-28 melanoma context, NHE1 is poised at the intersection of oncogenic signaling and pH-dependent malignant phenotypes. The BRAF V600E mutation drives constitutive ERK signaling, which can phosphorylate and activate NHE1, sustaining an elevated intracellular pH that favors actin polymerization and invasive behavior. Loss of SLC9A1 disrupts this protumorigenic loop, impairing pH-regulated migration, invasion, and possibly resistance to apoptosis. This knockout cell line thus provides a genetically clean platform to interrogate NHE1-dependent processes without off-target pathway perturbation, enabling precise dissection of its role in melanoma progression and response to targeted therapies.

Researchers can employ the SLC9A1 Knockout SK-MEL-28 Cell Line in diverse experimental workflows, including pHi measurements with BCECF fluorescence, Boyden chamber migration assays, Matrigel invasion assays, immunofluorescence staining of focal adhesions and actin, adhesion assays, and phospho-ERK flow cytometry. The model is well-suited for siRNA rescue experiments, NHE1 pharmacological inhibitor screening, and synthetic lethality studies under acidic tumor-mimetic conditions. Additional applications encompass western blotting and RT-qPCR to validate downstream signaling node alterations, and apoptosis assays to assess chemosensitivity. For further technical details or ordering information, please contact Ascent Research.